Manhattan BioSolutions, Inc. specializes in the development of next-generation antibody-drug conjugates (ADCs) that leverage evolutionary mechanisms to enhance cancer treatment. Their innovative ADCs are engineered to achieve precise tumor targeting and effective payload release, which allows for the selective destruction of cancer cells through various immune-mediated and direct anti-tumor strategies. This approach aims to improve therapeutic outcomes for patients with advanced cancers by minimizing damage to healthy tissues while maximizing the efficacy of the treatment.

In addition to their ADC technology, Manhattan BioSolutions is actively engaged in collaborations and partnerships to advance their research and development efforts. They have entered into agreements with notable institutions, including the National Institutes of Health and Binghamton University, to explore novel ADCs and innovative antibodies for targeted therapies. The company is also involved in the development of new linker-payload technologies and has received multiple grants to support their research initiatives, highlighting their commitment to pioneering advancements in oncology and therapeutic solutions.

United States

Biotech company delivering innovative precision biologics for patients with advanced, metastatic cancers

Manhattan BioSolutions, Inc.

Company Details